Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Lars P Kristensen"'
Autor:
Lars Erik Kristensen, Atul Deodhar, Ying-Ying Leung, Ivana Vranic, Mahta Mortezavi, Lara Fallon, Arne Yndestad, Cassandra D. Kinch, Dafna D. Gladman
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 487-499 (2024)
Abstract In this commentary, we review clinical data which helps inform individualized benefit–risk assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ORAL Surveillance, a safety trial of patients
Externí odkaz:
https://doaj.org/article/0dfdf61802f742879087a07fe9f0706d
Autor:
Inmaculada de la Torre, Ennio Lubrano, Rieke Alten, Lars Erik Kristensen, Baojin Zhu, Dennis G McGonagle, Jacques Morel, Vinod Chandran, Marcus Ngantcha, William Tillett, Walid Fakhouri, Nicola Gullick, Khai Jing Ng, Àngels Martinez Ferrer, Dominika Kennedy, Thorsten Holzkämper, Andris Kronbergs
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Background The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an interleukin (IL)-17A inhibitor (i) (IL-17Ai), approved f
Externí odkaz:
https://doaj.org/article/9fab36e7fb9744a09f21d6da08fe35fa
Autor:
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 617-632 (2024)
Abstract Introduction Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety. We present 100-week efficacy and safety results of risankizumab in patients with acti
Externí odkaz:
https://doaj.org/article/d175f505a9724186801cfc38fbee94d1
Autor:
Helle H Nielsen, Hans C Beck, Lars P Kristensen, Mark Burton, Tunde Csepany, Magdolna Simo, Peter Dioszeghy, Tobias Sejbaek, Manuela Grebing, Niels H H Heegaard, Zsolt Illes
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139659 (2015)
Inflammatory demyelinating diseases of the CNS comprise a broad spectrum of diseases like neuromyelitis optica (NMO), NMO spectrum disorders (NMO-SD) and multiple sclerosis (MS). Despite clear classification criteria, differentiation can be difficult
Externí odkaz:
https://doaj.org/article/0de9f23466e84c92a8c90d2a1defe7d5
Autor:
Joseph F. Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achie
Externí odkaz:
https://doaj.org/article/39e61f6277034f2f88e208b5a6fe086b
Autor:
David Thein, Nana A. L. Rosenø, Mia‐Louise Nielsen, Lars Erik Kristensen, Julia‐Tatjana Maul, Jashin J. Wu, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 857-863 (2023)
Abstract Background Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics. Objectives To map the overall treatment journey preceding the initiation of first
Externí odkaz:
https://doaj.org/article/6abf915d987d47869945d2dafe4986f2
Autor:
Jorge S Burns, Malthe Kristiansen, Lars P Kristensen, Kenneth H Larsen, Maria O Nielsen, Helle Christiansen, Jan Nehlin, Jens S Andersen, Moustapha Kassem
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21888 (2011)
Acquisition of a blood supply is fundamental for extensive tumor growth. We recently described vascular heterogeneity in tumours derived from cell clones of a human mesenchymal stem cell (hMSC) strain (hMSC-TERT20) immortalized by retroviral vector m
Externí odkaz:
https://doaj.org/article/140307d8b05347afacaabe04d4f442bd
Autor:
Lars Erik Kristensen, Jakob Kjellberg, Kirstine Amris, Pernille Hurup Duhn, Judi Olsen, Karoline Lolk
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective To assess the burden of illness of people with fibromyalgia (FM) and their spouses compared with selected match populations in Denmark.Methods Population-based, cohort case-control study using data from Danish registries from 1994 to 2021.
Externí odkaz:
https://doaj.org/article/08483a3239054e45900b760a009dc4f3
Autor:
Lars Erik Kristensen, Victoria Navarro-Compán, Marina Magrey, Andrew G. Bushmakin, Joseph C. Cappelleri, Arne Yndestad, Oluwaseyi Dina, Peter C. Taylor
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 1073-1087 (2023)
Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Using mediation modelling, we describe interrelationships between fatigue, pain, morning stiffness, C-reactive protein (CRP) and tofacit
Externí odkaz:
https://doaj.org/article/3c522789b45749f6a6d68b464bcbeb6a
Autor:
Lene Dreyer, Lars Erik Kristensen, Mark Andrew Ainsworth, Tanja Schjødt Jørgensen, Simon Francis Thomsen, Katrine Risager Christensen, Marie Skougaard, Zara R Stisen, Rebekka Lund Hansen, Mette Mogensen
Publikováno v:
BMJ Open, Vol 13, Iss 12 (2023)
Objectives Exploring patients’ perspectives for significant factors of relevance in living with a chronic disease is important to discover unmet needs and challenges. The primary objective of this study was to explore disease-related and treatment-
Externí odkaz:
https://doaj.org/article/877f7b18b4904b2ea1793f09a05ad214